Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.200 -0.130 (-3.00%)
Official Closing Price Updated: 4:15 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
News headline image
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
These AI-Related Stocks Were Down +10% Week Ending September 6 ↗
AI-related tech stocks plummeted this week with the August ISM manufacturing index report that figures that came in below consensus expectations raising fears about the strength of the economy and that... 
Via Talk Markets
Topics Economy
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
News headline image
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Recursion Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher ↗
 
Via Benzinga
News headline image
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Nasdaq Dips Over 2%; US Construction Spending Falls In July ↗
 
Via Benzinga
News headline image
Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On? ↗
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation... 
Via Benzinga
News headline image
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is Recursion Pharmaceuticals a Warren Buffett Stock? ↗
Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider. 
Via The Motley Fool
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
News headline image
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. ↗
Merging with a former rival will bolster its capabilities. 
Via The Motley Fool
News headline image
Is Recursion Pharmaceuticals Stock a Buy? ↗
We'll know a little more about the biotech's prospects in a year and a half. 
Via The Motley Fool
News headline image
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
News headline image
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
From FN Media Group LLC
Via GlobeNewswire
News headline image
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks ↗
Efficiency in core processes is set to increase substantially due to AI. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move ↗
There isn't much to suggest these businesses are actually vulnerable. 
Via The Motley Fool
News headline image
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? ↗
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals ↗
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million... 
Via Benzinga
Topics Artificial Intelligence
News headline image
RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024 ↗
RXRX stock results show that Recursion Pharmaceuticals met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Operational complementarities expected to yield annual synergies of approximately $100 million 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Is Recursion Pharmaceuticals a Millionaire-Maker? ↗
It's likely to experience a lot of growth. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.